Furthermore, the HER2+ BC in low IRPI group tended to be immunologically “hot”, which was more likely to benefit from anti-tumor immunity, while Herceptin-resistant BC with high IRPI tended to be immunologically “cold”, which was hard to benefit from anti-tumor immunity 44. The gene discussed is ERBB2; the disease is neoplasm.